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Abstract
Although it does not have a long history of sentinel node evaluation (SLN) in female genital system
cancers, there is a growing number of promising study results, despite the presence of some
aspects that need to be considered and developed. It has been most commonly used in vulvar and
uterine cervivcal cancer in gynecological oncology. According to these studies, almost all of which
are prospective, particularly in cases where Technetium-labeled nanocolloid is used, sentinel node
detection rate sensitivity and specificity has been reported to be 100%, except for a few cases. In
the studies on cervical cancer, sentinel node detection rates have been reported around 80–86%,
a little lower than those in vulva cancer, and negative predictive value has been reported about 99%.
It is relatively new in endometrial cancer, where its detection rate varies between 50 and 80%.
Studies about vulvar melanoma and vaginal cancers are generally case reports. Although it has not
been supported with multicenter randomized and controlled studies including larger case series,
study results reported by various centers around the world are harmonious and mutually
supportive particularly in vulva cancer, and cervix cancer. Even though it does not seem possible
to replace the traditional approaches in these two cancers, it is still a serious alternative for the
future. We believe that it is important to increase and support the studies that will strengthen the
weaknesses of the method, among which there are detection of micrometastases and increasing
detection rates, and render it usable in routine clinical practice.
Background
Sentinel lymph node is the first node where primary
tumor lymphatic flow drains first, and therefore the first
node where cancer cells metastasize. Lymphatic metasta-
sis has always been a focus of interest for the surgeons, as
it is one of the first and foremost routes of spreading in
many tumors and, because it shows the level of spreading.
The condition of the lymph notes has vital importance in
the planning and management of the treatments of many
cancers.
Lymphatic mapping is the passage of a marking dye or
radioactive substance, injected by a tumoral or peritu-
moral injection, through the lymphatic vessels draining
the primary tumor, that is, afferent lymphatic vessels, to
the sentinel lymph node. This lymph node is the one with
the highest possibility of involvement in case of metasta-
sis from the primary tumor. According to lymphatic map-
ping hypothesis, if the sentinel node is negative in terms
of metastasis, then non-sentinel nodes are also expected
to be negative in that regard. However, there may be
metastasis in the non-sentinel nodes even when the senti-
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both explicable and inexplicable. Therefore there are
reports of false negativity in literature studies [1].
Sentinel lymph node biopsy concept was first developed
to identify lymphatic metastasis in parotid carcinoma [2].
Later on, it has been used in penile carcinoma, breast,
melanoma, lung, gastrointestinal, endocrine and gyneco-
logical cancers. Results of the studies about and experi-
ences in gynecological cancers, particularly vulva cancer,
and cervix cancer, as well as endometrial cancer, but to a
lesser degree, have been published in the literature. The
present study focused on the literature data about the
results of the use of sentinel lymph node biopsy concept
in gynecological cancers.
Technique
Several techniques have been reported to identify the sen-
tinel nodes. These are blue dye labeling, radiolabeling and
combined labeling that comprise sequential application
of blue dye and technetium labeling. Most basically, a
vital dye like isosulfan blue is injected into intact tissue
that around of tumor intra-operatively. The injections are
made in to junction of the tumor and normal tissue in vul-
var lesions, peritumoral cervical stroma in cervical cancer
circumferentially. In the case of endometrial carcinomas
the site of injection are not as well defined. This substance
is inert, and rarely causes allergic reactions. Studies report
that the highest rate of allergic reactions is 3% [3]. The dye
injected reaches the lymph node through microlymphat-
ics in about 5 minutes and the median stain time of dye
in the sentinel lymh node is 21 minutes [4].
The second type of mapping is injection of a radiocolloid
or both. This procedure requires peritumoral injection tis-
sue that surrounding the tumor of 99mTC (Technetium)
labeled colloids such as sulfur colloids, albumin colloids
or carbon colloids. Although a number of protocol varia-
tions have been reported, radiocolloid is injected usually
2–4 h preoperatively if 99mTc sulfur colloid is used and on
pre-op day 1 if 99mTc albumin is used. Radiocolloid trans-
ported to the sentinel node is identified with a gamma
counter applied to the patient. The time interval for max-
imum tracer accumulation in sentinel node is 1.5 hour
after injection [4]. The particle size of labeled colloid is
important and the time interval between aplication and
detection is affected from particle size. It has not beeen
detected any sentinel nodes in the paraaortal region simi-
larly if particles over 200 nm [5].
If the radioisotopes are employed, a preoperative radiol-
ymphoscintigram is performed to detect in localization of
the sentinel node(s). Pre-operative lymphoscintigraphy is
particularly useful in cases where the primary tumor has
more than one drainage. If a preoperative radiolympho-
scintigram was performed, this image is used to guide the
site and size of the incision and to localize the sentinel
node in vulvar cancers. Mostly, dissection of the sentinel
node is performed during of surgery in the operation
room. The organization of preoperative radiocolloid
application and subsequent lymphoscintigraphy is diffi-
cult and costly. It has been reported that "Short Tc proto-
col" without preoperative lymphoscintigraphy has a high
detection rates, an easier management and is cost effective
[5].
The using of laparoscopic gamma probe is very important
alternative in the minimally invasive procedures. After
sentinel node is detected and excised gamma counter is
used to assess for background radiation that indicates if
the correct node has been removed or if there is another
sentinel node. The background radiation count should
not exceed 10% of the count from the sentinel node.
Nodes are usually re-examined with the probe ex vivo to
confirm radioactivity, and the lymphadenectomy site is
reassessed to exclude residual radioactivity. Sentinel
nodes are sent for pathological evaluation as separate
specimens [6].
Vulva cancer
Vulvar carcinoma affects 4% of all gynecological cancers,
and is in the fourth most common female genital cancer.
Of the cases, 90% are squamous cell carcinomas, while
the rest are melanoma, adenocarcinoma, basal cell carci-
noma and sarcoma [7].
Nodal metastasis in vulva cancer is the main prognostic
factor, irrespective of the size of the primary tumor, and its
presence is markedly correlated with survival. Five-year
survival was reported 90% in those without inguinal node
involvement, 80% in those with two or more nodal
involvements, and 12% in those with three or more nodal
involvements [6-8]. The risk of involvement is 11% in
stage I cases and 25% in stage II cases with stromal inva-
sion over 1 mm. For this reason lymph node dissection
should be performed in addition to local excision [6].
Although less radical approaches have been developed
with increasing frequency particularly in the last 25 years,
postoperative complications still occur at a remarkable
rate. Complications like 69% leg edema and 85% injury
opening reported in the classical treatment of vulva cancer
were reported 19% and 29%, respectively, in a study by
GOG, where radicalness was reduced with radical hemi-
vulvectomy and ipsilateral lymphadenectomy in clinical
stage I cases [9-12]. However, for the time being, there is
not any non-invasive technique that can reliably show
nodal metastases. In a metaanalysis carried out by Selman
et al., sensitivity and specificity of methods used to iden-
tify nodal metastasis were reported 72% and 100% in finePage 2 of 12
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tomography, 86% and 87% in magnetic resonance imag-
ing, 45–100% and 58–96% in ultrasonography [1].
Therefore, non-invasive and/or micro-invasive methods
are studied in the hope that they will reduce complica-
tions, in addition to exercising a positive effect on survival
of patients with vulvar cancer. Of these, the most contem-
porary and promising method is sentinel lymph node
biopsy.
Its applicability has been demonstrated firstly by Leven-
back et al., using isosulfan blue dye on 9 vulvar cancer
patients, of whom 7 had squamous cell carcinoma and 2
had melanoma [13]. About a year later, the same authors
published a second report on 21 vulvar cancer patients.
This study which reported the results of using intra-oper-
ative lymphatic mapping with isosulfan blue dye,
included 9 T1 cases, 10 T2 cases and one T3 case, as well
as one case who had undergone local excision and there-
fore was not known. Of the lesions in the cases, 10 were
lateral and 11 were midline. The study reported a 62%
sentinel node detection rate and 100% sensitivity and spe-
cificity. It was stated that the cases who had negative sen-
tinel node were not found to have metastasis in non-
sentinel nodes. Sentinel nodes were identified in different
areas of the superficial compartment [14].
Sentinel node detection rates as low as 60% and rates of
failure to detect sentinel node as low as 40%, found in
sentinel node studies using isosulfan blue, have caused
disappointment at first [1]. DeCesare et al., demonstrated
the applicability of intra-operative gamma ray use, and a
year later, Hullu et al., demonstrated the applicability of a
combined technique that included pre-operative lympho-
scintigraphy and intra-operative blue dye methods
[15,16]. It has been reported that avarage detection rate of
sentinel nodes in a literature review of vulvar cancers is
85% with blue day only, 99% with radiolabeled (with or
without blue day) [17].
At present, quite high identification rates [1] and low false
negativity rates are reported in sentinel node procedure
employing the combined technique. Puig-Tintore et al.,
reported in a study including 26 patients with vulvar squa-
mous cell carcinoma that sentinel node was detected in
96% of the patients with technetium-99m-labeled (99mTc)
and blue dye peritumoral injection. Of these nodes, 76%
were unilateral, and 24% were bilateral. It was reported in
the concerned study that all non-sentinel nodes were
found negative in cases who were not clinically suspected
and who had negative sentinel lymph node [18].
In this respect, sentinel lymph node biopsy is a method
that needs to be studied and developed, while it must be
stressed that large studies are needed to reveal sensitivity,
specificity, positive and negative predictive values. How-
ever, both the rare incidence of vulva cancer relative to
other gynecological cancers and the requirement of a dis-
tinct experience for this method limit access to such infor-
mation. The studies associated with vulvar cancer that
included more than 20 cases were presented Table 1.
Although lymphatic mappings appear promising in the-
ory, it has some aspects, which overshadow its success and
prevent its liberal use. The first of these aspects is the
learning curve. In a sentinel node study carried out using
intra-operative isosulfan blue, sentinel nodes were identi-
fied in 22 out of 25 patients with a lateral tumor, and 24
out of 27 patients with a midline lesion, consequently in
46 out of a total of 52 patients (88%), False negativity was
0%. The same study failed to identify sentinel nodes in 2
out of 12 groins, which had been proven to have meta-
static disease. The authors attributed this to their being in
the first two years of the study [12]. The second aspect is
false negativity. Although it is reported more commonly
in patients in whom blue dye is used, it was also noted in
studies where radioactive substance was employed. In two
studies with more than 50 cases, Ansink et al., reported
false negativity in 2 cases in a 51-case series, and Leven-
Table 1: Literature review of Sentinel node detection in vulvar cancers (Only Studies with more than 20 patients were presented)
Author Year Detection 
method











Levenback [14] 1995 BD - 21 29 66 5 0 100 (-)
De Hullu [16] 1998 ILS+ BD Nanocolloid 59 107 100 24 0 100 (+)
Ansink [20] 1999 BD - 51 93 56 9 2 95 (-)
Levenback [19] 2001 BD - 52 76 88 10 2 100 (+)
Sideri [27] 2000 ILS Colloid albumin 44 77 100 13 0 100 (-)
De Cicco [28] 2000 ILS Colloid albumin 37 55 100 8 0 100 (-)
Sliutz [29] 2002 ILS+ BD Microcolloidal 
albumin
26 46 100 9 0 100 (+)
Puig-Tintore [18] 2003 ILS + BD Nanocolloid 26 37 96 8 0 100 (+)
Moore [30]] 2003 ILS + BD Sulfur colloid 21 31 100 7 0 100 (+)
Hauspy [31] 2007 ILS+ BD Sulfur colloid 41 68 95 18 0 96 (+)
Abbreviations ; BD: blue dye method, ILS: intraoperative lymphoscintigraphy, NPV: negative predictive value, SN: sentinel node, (+): yes, (-):No,Page 3 of 12
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[19,20].
The third and maybe the most current aspect is the case of
patients who are found negative in terms of metastasis on
histopathological evaluation, but are identified by ultrast-
aging to have metastasis at the micro level. In the study by
Puig-Tintore et al., rate of micrometastasis identifiable by
ultrastaging was established as high as 38%. The con-
cerned study which included squamous cell vulvar carci-
noma patients found sentinel lymph nodes in 96% of the
cases with m and blue dye peritumoral injection. Of these
nodes, 76% were unilateral, and 24% were bilateral. In
the study, all the non-sentinel lymph nodes were found
negative in cases who were not clinically suspected and
whose sentinel lymph nodes were negative. Negative pre-
dictive value was reported 100% [18]. When the patho-
logically negative sentinel nodes were subjected to
microstaging with serial sections, and immunochemically
stained with cytokeratin, micrometastasis was found in
11% of sentinel nodes, which were negative by hematox-
ylin eosin stain [21]. In a study by Terada, sentinel lymph
nodes were made in 10 cases, and sentinel nodes were
obtained in all. One node was found positive and the oth-
ers negative by conventional staining. Serial sectioning
and immunohistologic staining showed two metastases in
these cases. Two out of the three positive nodes could not
be identified by conventional histopathological evalua-
tion [22].
Recurrence was reported 6% in cases in whom sentinel
lymph node biopsy was conducted. Of the 52 cases
included a sentinel lymph node study by Frumovitz et al.,
those who had recurrence were reported in a study. It was
noted in the concerned study that of the cases in whom
lymphatic mapping was conducted, recurrence developed
in three cases with squamous vulvar cancer. A retrospec-
tive investigation revealed that one of these cases had pos-
itive SLN, positive non-SLN and extracapsular disease,
and was at high risk for recurrence, the other was a case in
whom sentinel node was not identified, and the third was
a case who had negative sentinel node and negative non-
sentinel node. It was reported that the last case was iden-
tified to have bilateral sentinel node in the clitoral lesion,
and was negative in the conventional histological evalua-
tion [23].
In conclusion, sentinel lymph node concept that was
developed to avoid severe complications like injury infec-
tions, injury opening and lymphedema caused by
inguinofemoral lymphadenectomy performed in addi-
tion to radical vulvectomy in vulvar cancer, which is seen
rarely relative to other gynecological cancers, but is an
extremely destructive disease, is a promising method in
terms of its applicability in routine clinical practice.
Micrometastasis, which overshadows the success of the
method, appears like a problem that can be overcome by
ultrastaging and immunohistochemistry. A study compar-
ing complete inguinofemoral lymph node dissection and
sentinel node procedure results did not show any differ-
ence between the rates of metastatic lymph nodes excised
by two methods, whereas identification of micrometas-
tases was found higher by sentinel node biopsy and
ultrastaging, than by complete inguinofemoral lymph
node dissection [24].
An extensive phase III study, exploring the negative pre-
dictive value of a negative sentinel lymph node in stage I
and II invasive squamous cell vulvar cancers and the local-
ization of the sentinel node in these patients, is still under
way in the National Cancer Institute (GOG-173).
Vulvar melanoma
This is the second most common vulvar cancer after squa-
mous cell cancer. The only effective treatment among
available treatments is surgery, and the role of elective
lymphadenectomy is debatable. Thus, there is only lim-
ited experience with sentinel lymph node. One of the
major studies in the literature is the one conducted by De
Hullu et al., [25]. In the concerned study, complete
inguinofemoral lymph node dissection was performed in
three cases, who had positive sentinel node, out of 9 vul-
var melanoma cases. All of the dissected sentinel nodes
were found negative in terms of metastasis in routine his-
topathologic examination in these cases, except for one, in
whom additional nodal metastasis was detected. Immu-
nohistochemical investigations of these nodes conducted
by step-sectioning and S-100 and HMB-45 were also
found negative. Follow-up of the cases who underwent
sentinel node procedure showed recurrence in two
patients. Authors of the study recommended the use of
sentinel lymph node procedure only within the context of
clinical studies. In another study, Abramova et al.,
described experiences with lymphatic mapping and the
following sentinel node biopsy procedure using 99mTc -
labeled sulfur colloid in 6 patients with vulvar melanoma.
These researchers who also collected the cases in the liter-
ature reported that the success in identifying the localiza-
tion of the sentinel node was about 100% [26]. Other
series on vulver cancer are drtailed in table 1[27-30]
Cervical cancer
Pelvic nodal involvement in early stage cervical cancers
eligible for surgery was reported 0–4.8% in Stage IA, 17%
in Stage IB, 12–27% in IIA and 25–30% in IIB [31,32].
Basically, systemic retroperitoneal lymph dissection is
performed in all these cases to identify nodal involve-
ment, which is seen at a rate of 0–4.8% in Stage IA. This
means that the performed lymphadenectomy procedure
will not benefit more than 90% of cases, and besides,Page 4 of 12
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operation time, blood loss, blood transfusion, lym-
phocyst, and lymphedema. Therefore, sentinel lymph
node procedure aimed to reveal the nodal condition has
been an increasingly popular topic of research in cervix
cancer on the same grounds with vulvar cancer. It has
been presented literature review of sentinel node detec-
tion in cervical cancer in table 2.
Sentinel lymph node biopsy, which is less invasive and
cheaper, and has a lower rate of morbidity. However,
some serious restrictions need to be clarified for the
method to be applicable in clinical practice. The main
restrictions include distribution of sentinel lymph nodes
over a wider area due to the lymphatic distribution of the
cervix, localization of the tumor in the cervix, and a result-
ing lower detection rate, and sensitivity, as well as higher
false negativity. These conditions are complementary to
the technique and are used to evaluate the dissected
lymph nodes.
The known lymphatic distribution of the cervix has three
different lymphatic patways have been identified; laterally
to external iliac and common iliac nods, internally to the
hypogastric nodes, and posteriorly to the pre-sacral and
then para-aortic nodes. Although majority of the nodes
are located in internal iliac and external iliac areas, nodes
have been found in also presacral, parametrial and parar-
ectal areas [33]. In a sentinel node study carried out with
26 patients using combined technique, Rhim CC et al.,
found that of the sentinel nods 18 were in the external
iliac, 12 in the obturatory, 8 in the internal iliac, 8 in the
parametrial, 2 in the common iliac and one in the
inguinal lymph nodes [34]. In a study by O'Boyle et. al.
17% of the sentinel nodes were found in the common
iliac area, 62% in the external iliac, 4% in the internal
iliac, and 17% in the parametrial areas [35], whereas Lev-
enback found 9% of the sentinel nodes in the paraaortic
area, 11% in the common iliac, 71% in the external iliac,
and 9% in the parametrial area in a study including stage
IA-IIA cases [36]. Martinez Palones found in his study
with 26 cases that of the sentinel nodes, 40% were in the
internal iliac and 25% were in the external iliac area [37].
Barranger obtained 67% of the sentinel lymph nodes in
the external iliac area, 28% in the internal iliac area, and
5% in the common iliac area [38]. Although different
studies report different results, sentinel lymph nodes are
most commonly identified in the external iliac area,
which is followed by common iliac and parametrial areas,
in most of the studies. These localizations are consistent
with the results obtained by conventional complete lym-
phadenectomy [38-41]. In their study Rhim et al.,
reported that of the 21 cases whose sentinel lymph nodes
were found negative, pelvic lymph nodes were also nega-
tive in all, but one case. Of the 5 cases whose sentinel
lymph nodes were positive, 4 were found to have pelvic
lymph nodes positive, and one negative. In this study sen-
tinel node detection rate was reported 94%, overall accu-
racy 97%, and false negativity 4.76% [34].
Presence of micrometastases has been reported in sentinel
node studies including cervical cancer cases as well. In the
lymphatic mapping study conducted by Silva et al., using
99mTc labeled phytate, it was reported that micrometas-
tases were established by cytokeratin immunohistochem-
ical in 5.1% of the sentinel lymph nodes which were
Table 2: Literature review of sentinel node detection in cervical cancers (Only Studies with more than 20 patients were presented)
Author Yıl Detection 
method















Malur [44] 2001 ILS or BD Albumin-RES LT/LS 50 PN+PAN 80 6 1 97 (-)
Rhim [34] 2002 ILS + BD Colloid albumin LT 26 PN+PAN 100 5 1 95 (-)
Levenback [36] 2002 ILS + BD Radiocolloid LT 39 PN+PAN 100 8 1 97 (+)
Plante [2] 2003 BD Antimony 
trisulfide colloid
LS 41 PN+PAN 79 12 0 100 (+)
Martinez-Palones [37] 2004 ILS + BD Colloid albumin LT/LS 25 PN+PAN 92 4 0 100 (+)
Chung [48] 2003 ILS + BD Sulphur colloid LT 26 PN+PAN(bif
urcation)
100 1 0 100 ?
Buist [49] 2003 ILS + BD Colloid albumin LS 25 PN 100 9 1 94 (+)
Hubalewska [50] 2003 ILS + BD Nanocolloid LT 37 PN+PAN 100 5 ? ? ?
Van Dam [51] 2003 ILS Nanocolloid LS 25 PN 84 5 0 100 ?
Marchiole [53] 2004 BD - LS 29 PN 100 2 3 87.5 (+)
Niikura [54] 2004 ILS + BD Phytate LT 20 PN 90 2 0 100 (+)
Pijpers [55] 2004 ILS + BD Colloid albumin LS 34 PN 97 17 1 92 ?
Silva [42] 2005 ILS Phytate LT 56 PN 93 10 3 92 (+)
Rob [5] 2005 BD - LT/LS 100 PN+PAN 80 20 1 99 (+)
Di Stefano [56] 2005 BD - LT 50 PN 90 9 1 97 (+)
Angioli [57] 2005 ILS, (LS+BD) Colloid albumin LS 37 (83) PN 70 (96.4) 9 (15) 0 (0) 100(100) (+)
Lin [58] 2005 ILS Sulfur colloid LT 30 PN 100 7 0 100 (+)
BD: blue dye method, ILS: intraoperative lymphoscintigraphy, LS: laparoscopy, LT: laparotomy; NPV: negative predictive value, SN: sentinel node, (+): yes, (-):No, ?: Unknown, 
PN: Pelvic lymph node dissection, PAN: Para-aortic lymph node dissectionPage 5 of 12
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44% of the sentinel nodes were found in the external iliac,
39% in the obturatory, 8.3% in the internal iliac and 6.7%
in the common iliac area, and sensitivity was reported
82.3%, NPD 92.1%, and accuracy of sentinel node in pre-
dicting lymph node condition 94.2% [42]. In the study by
Levenback, sentinel node sensitivity was found 87.5%,
negative predictive value 97%, and false negativity 11%
[36], while Ying et al., established in their study that the
detection rate of sentinel lymph node biopsy was 75%,
and sensitivity, specificity and accuracy were 75%, 100%
and 95%, respectively [43].
Not only the amount of blue dye used in sentinel node
studies in cervical cancer affects the rate of identified sen-
tinel nodes, but also use of radioactive isotope instead of
dye as a marker influences the sentinel node detection
rate. In a study where they conducted sentinel node
research with Patent Blue Violet in all cases before sys-
temic lymph node dissection, Dargent et al., investigated
the changes in sentinel node detection rate in proportion
to the amount of dye used. They reported that when they
used 1.5 ml of dye or less, they found 50% of the sentinel
nodes, and when they used 4 ml of dye, they found 90%of
the sentinel nodes [39]. Malur et al. studied sentinel node
detection rate, sensitivity and negative predictive value
using radioactive isotope instead of dye only, and a com-
bination of the two [44]. Sentinel node detection rate in
this study was 55% with blue dye only, 76% with radiola-
beled and 90% with the combined technique. Sensitivity
and negative predictive value, which were 83.3% and
97.1% respectively, reached 100% when dye and radioac-
tive isotope were used in combination. Similarly, false
negativity rate, which was 16% dropped to 0%. In a study
by Plante et al., the detection rate which was 79% by dye
alone rose to 93% with the addition of lymphoscintigra-
phy. Negative predictive value of the combined technique
was reported at 100% [3]. Likewise, in a study by Lam-
baudie et. al., sensitivity was 33%, specificity 100%, PPD
100%, and NPD 100% when dye was used alone, as
opposed to dye and isotope combination where sensitiv-
ity was 66%, specificity 100%, PPD 100%, and NPD 90%
[45].
Use of laparoscopy with a view to making the procedure
less invasive has also been investigated in sentinel node
biopsy studies. In this context Barringer et al., conducted a
sentinel node study using radioactive isotope and patent
blue combination with the help of an endoscopic gamma
probe before complete laparoscopic pelvic lymphadenec-
tomy in 13 patients. Twelve out of 13 patients were found
to have sentinel lymph nodes (92%). One patient was
found to have only one microscopic metastasis by immu-
nohistochemical examination [38]. In short, detection
rate, sensitivity, specificity, and negative predictive value
are reported to increase, while false negativity decreases in
studies where lymphoscintigraphy is added to blue dye
use. Allergic reaction at a rate of 3% and the longer learn-
ing curve reported in dye use indicate that radioisotope is
more advantageous in cervical cancer [3]. Previous coniza-
tion and stage is not necessarily a cause of failure. Effect of
diagnostic conization, on the sentinel node detection rate
is controversial. I has been reported no advers effect in
most of studies associated with previous conization
[36,39,45], whereas in a study lower detection rate has
been founded [46].
Addition of such modalities as radioisotope use and
laparoscopy use to sentinel node studies in cervical cancer
helps to increase the success of the method. In order to
further develop the method, progress should be achieved
in increasing the accuracy of frozen examinations in sen-
tinel node procedure, as whether or not to continue to
lymphadenectomy should be decided on the basis of the
information pertaining to the sentinel node. Sensitivity
and specificity of the sentinel node frozen biopsy are cur-
rently reported 95.2% (20/21) and 80% (4/5) in cervical
cancers respectively [34]. However, it may be difficult to
identify metastases by sentinel node frozen biopsy. Multi-
ple cross sections of the dissected node and immunohis-
tochemical staining may help compensate for this false
negativity, although these methods are time-consuming
and do not seem practical for the purposes of frozen
biopsy.
Determining sensitinel node using preoperative SPECT/
CT lymphoscintigraphy is the newest progress in sentiti-
nel node of cervix cancer. This Technique is very similar to
conventional nuclear medicine planar imaging using a
gamma camera. However, it is able to provide true 3D
information. Kushner et al studied in 20 cases and they
found sensitinel node: 33% as obturauar, 30% as external
iliac, 19% as internal iliac area. Interestingly sensitinel
node were found in unusual area, e.g.11% as common
iliac, 5% as presacral, 3% paraaortic. In this study, lym-
phoscintigraphy detection rate was reported as 100%
NPD [47]. In conclusion, in order for sentinel node
biopsy to replace conventional approaches with its practi-
cality and reliability, prospective studies with larger case
series are needed in cervical cancers. Other studies are
detailed in table 2[48-58].
Endometrial cancer
Endometrial cancer is the most common gynecological
cancer in industrialized countries. Involvement of pelvic
and paraaortic lymph nodes is a very important prognos-
tic parameter in endometrial cancers. Upstage resulting
from nodal involvement was found in 12.4% of clinical
stage I cases, and 27.3% of clinical stage II cases [59].
Therefore, the stage should be exactly determined in orderPage 6 of 12
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and to plan adjuvant treatments. Lymphadenectomy pro-
cedure is the standard in staging surgery to reveal the con-
dition of the lymph nodes. As in other gynecological
cancers, increase in morbidity and complications associ-
ated with lymphadenectomy have led to research about
the less invasive sentinel node concept in endometrium
cancer.
Since the lymphatic network of the uterus is more com-
plex than that of the cervix and vulva, and it is more diffi-
cult to access the dye or radioisotope injection area,
sentinel lymph node studies in endometrial cancers are
rarer, relative to those in other cancers. In a study where
sentinel node examination was conducted in 15 high-risk
endometrial tumor cases using subserosal isosulfan blue
dye injection during laparotomy, 10 cases (67%) were
found to have dyed lymph nodes, and of a total of 31
lymph nodes dissected from these cases, 12 were reported
to be in the paraaortic area, 6 in the common iliac area,
and 13 in the pelvic region. [60]. In a lymphatic mapping
study where patent blue-V was injected into the uterine
wall by laparoscopy, instead of laparotomy, in 8 cases, 5
cases (62.5%) were found to have sentinel nodes in the
obturatory, internal iliac and common iliac areas [61].
In their study where they explored the changes in sentinel
node detection rate by the injection site of patent blue-V
dye, Holub et al., injected patent blue-V dye into the sub-
serosal myometrium in 13 out of 25 patients, and into the
cervico-subserosal myometrium in 12 patients. Sentinel
node detection rate was 61.5% in the subserosal myo-
metrium group, and 83.3% in the cervico-subserosal myo-
metrium group. Although there was not any statistical
difference between the groups, it was reported that the
mean number of sentinel nodes identified per case was
significantly higher in the cervico-subserosal myo-
metrium group [62]. In another study, by Gien et al., iso-
sulfan blue dye injection was made by hysterescopy
during laparotomy into the peritumoral endomyo-
metrium, subserosa, or both in 16 cases. Sentinel nodes
were identified in 56% of the cases to whom only serosal
injection was made, and 50% of those in whom both
serosal and hysterescopic injection were made. Overall
sentinel node detection rate was found 44%, and negative
predictive value, 86% [63].
Microscopic metastasis has been explored in sentinel
node studies with endometrium cancer. In a laparoscopic
sentinel node study where a total of 11 cases, of whom 10
were stage IB and one stage IIA, were injected with re-
operative radioactive isotope and intra-operative blue
dye, Pelosi et al., found metastases in three out of 17
lymph nodes (17.5–6%), of which 6 were bilateral and 5
were unilateral [64]. Again, Pelosi et al., investigated the
prognostic role of sentinel lymph node biopsy procedure
in a study where sentinel nodes, all of which were in the
internal iliac lymph nodes of 15 out of 16 patients
(93.7%) were identified by lymphoscintigraphy and
laparoscopically-assisted intra-operative sentinel lymph
node biopsy in 16 patients with FIGO IB endometrial can-
cer. They found micrometastases in 3 out of the 24 lymph
nodes, and reported that there was no relapse in the 12
cases whom they could follow-up [65]. In another study
where sentinel node was explored by pre-operative lym-
phoscintigraphy and intra-operative gamma probe, senti-
nel nodes were identified in 82% of the 28 endometrial
cancer cases. The tumor in 95% of the cases in whom sen-
tinel nodes were identified was found to have 50% inva-
sion. These researchers attributed the high identification
rates to the sentinel node modality and hysterescopy they
used [66].
In a prospective study where they examined sentinel
lymph nodes by hysterescopic pre-operative peritumoral
m Nanocolloid injection and lymphoscintigraphy, Fersis
et al., reported 85.7% sensitivity [67]. In another sentinel
node study that used the combined technique, hystere-
scopic subendometrial peritumoral m -Nanocolloid and
blue dye injection in 26 cases, sensitivity was reported
100% [68]. The fact that involved lymph nodes in the
endometrium are examined over a wide retroperitoneal
area in cases where blue dye is used brings about a serious
decrease in the detection rate due to the dye's rapidly pass-
ing through the lymphatics. Although pre-operative lym-
phoscintigraphy seems more sensitive than blue dye, it
has been argued that intra-operative follow-up with a
gamma probe is even more sensitive. In a study by Nikura
et al., sentinel nodes that could not be identified by pre-
operative scintigraphy in 4 cases were identified intra-
operatively [66].
An interesting case reported by Van Dam et al., has added
a different dimension to the sentinel node concept. A case
of stage IB, grade 2 endometrial cancer, who was treated
with total abdominal hysterectomy, bilateral salpingoo-
pherectomy, pelvic node sampling and vaginal vault radi-
ation, and developed mid-vaginal recurrence after the
treatment, was studied in terms of selective lymph node
by peritumoral technetium nanocolloid injection, and
was found to have a total of 3 sentinel nodes, two in the
left obturatory fossa and one in the right external iliac
region. When these were found normal on histology, total
vaginectomy, parametrectomy and pelvic lymphadenec-
tomy were performed [69]. In conclusion, although
results of studies about sentinel node research in endome-
trial cancer are promising, though not to the same extent
with those in vulvar and cervical cancers, further studies
are needed.Page 7 of 12
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Number of literature studies about sentinel node proce-
dure in vaginal cancer patients is fairly scarce. Of these,
the main study is the one where Vam Dam et al., reported
4 cases. In the concerned study, sentinel node procedure
was performed in primary and recurrence vaginal cancer
cases. In all cases, pre-operative 60-mBq technetium-
labeled nanocolloid injections were made at 3, 6, 9, 12
hour lines, adjacent to the cancer in the vagina, which was
followed by dissection of sentinel nodes laparoscopically
or with a handheld probe. Sentinel nodes could be iden-
tified in two out of the three patients. Sentinel nodes were
found in the groin and obturatory area in one case, and
just below the junction of iliac vessels in the other. Senti-
nel node could not be identified by lymphoscintigraphy
in one patient. Sentinel node procedure could not be con-
ducted in one patient who was treated with combined
chemo-radiotherapy initially, but showed recurrence 6
months later. In this patient, a sentinel node was identi-
fied in the right obturatory area during staging procedure,
and was dissected laparoscopically. Localizations of the
sentinel nodes identified in this study, which were exter-
nal iliac region and groin in distal vaginal cancers, and
obturatory fossa and external iliac region in proximal vag-
inal cancers, are consistent with our previous knowledge
[70].
Paradoxial conditions in sentinel node biopsy
Although according to sentinel node hypothesis the
metastasis in the first node draining the tumor is identi-
fied, this is not always the case. There are many cases
which cause sentinel node procedure to give false negative
results, or where sentinel node cannot be identified. It was
reported in a study including vulvar cancer cases that the
metastatic lymph node identified by palpation intra-oper-
atively could be bypassed due to lymphatic stasis caused
by hardening associated with metastasis, or that sentinel
node could not be identified due the stasis of the lym-
phatic flow [71,72]. Pre-operative and post-operative pal-
pation is important in sentinel node examination due to
such findings. Similarly, pre-operative computerized tom-
ography and magnetic resonance imaging can be consid-
ered, or nodal biopsy in the accompaniment of USG can
be carried out in cases with enlarged lymph nodes. In a
study including cervical cancer patients Plante et al., found
that the rate of sentinel node detection in the dissection
area of the patients who had nodes that appeared normal
on laparoscopy was 75% and sentinel node detection rate
in patients with macroscopic involvement was 75% [3].
Similarly it was noted that sentinel node detection rate
decreased in endometrial cancers, where sentinel node
experience is lower relative to other gynecological cancers,
due to an impairment of the lymphatic flow when myo-
metrial invasion is above 50% [66]. Another finding is
that the histopathological examination of a sentinel mass
formed by two lymph nodes revealed by lymphoscintigra-
phy showed that one the concerned nodes was sentinel
and the other was non-sentinel. Complete sentinel node
dissection will be appropriate in such cases. Besides, the
pathologists who conduct the frozen examination should
be informed about the number of dissected sentinel
nodes. In addition, increased Body Mass Index has a
reductive effect on sentinel node detection. Pre-operative
USG and directed biopsy can be utilized to decrease these
negative results [71].
Why are micrometastates important and how 
should the future be?
According to sentinel node concept, negativity of the sen-
tinel lymph node requires other nodes to be negative in
terms of metastasis. However, microscopic metastasis in
the sentinel node might be interpreted as negative, when
evaluated by classical hematoxylin eosin. This is an
important condition, and there may be metastasis in non-
sentinel nodes in case that there is microscopic metastasis
in the sentinel nodes. Indeed, there is no special defini-
tions associated with micrometastases, macrometastases
or submicrometastases in gnecologycal cancers and use
accepted criterions in breast cancers. According to the
Philadelphia Consensus Conference about sentinel node
in breast cancer; Any cluster of malignant epithelial cells
less than 2 mm in size was designated as mikrometastasis.
Inside this category of metastases, any cohesive cluster of
malignant cells that 200 μm or less in size was designated
as submicrometastases [73]. This is very important clini-
cally. Likewise, in a study by Robinson, a metastasis
smaller than 2 mm was found in the inguinal node, and
metastasis was identified in another inguinal lymph node
in this case [24]. Besides, it has been shown in many stud-
ies that micrometastasis poses an increased risk in terms
of recurrence. In their study including cervical cancers,
Juretzka et al., reported that recurrence developed in 50%
of patients with micrometastasis, and 6.7% of those with-
out micrometastasis [74]. Similarly, relative risk of recur-
rence was reported 2.44 in early stage cervix cancers,
which do not have nodal metastasis in the histopatholog-
ical evaluation, but do have nodal micrometastasis, and
2.22 in the presence of submicrometastasis [75]. In
another study, it was reported that recurrence risk in vulva
cancers, where there was not nodal involvement histolog-
ically, but presence of metastasis was shown, increased 20
folds relative to the risk in those who do not have
micrometastasis [76]. It has been reported that prognostic
value of micrometastasis is controversial in some studies
[3]
Given the starting point of sentinel lymph node concept,
microscopic metastases that dwarf the applicability of the
method become more important. This condition which
causes false negativity is still pertinent to many tumors.Page 8 of 12
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ping concept can lend credibility to the method's applica-
bility. It has been argued that the issue can be resolved by
the addition of a histopathological ultrastaging protocol
to the sentinel node procedure. In Terada's study, 2 out of
14 cases found negative by conventional staining were
found positive by ultrastaging, where cross sections are
prepared thinner [22]. Van Deist et. al. suggested prepara-
tion of additional cross sections with 250 μ intervals and
immunohistochemical staining with cytokeratin [77].
However, these methods are time-consuming, and should
be balanced with output. Nevertheless, it is also possible
to find occult lymph node metastases in 23% of the
patients, when the lymph nodes found negative by hema-
toxylin eosin are stained with cytokeratin AE1/AE3 and
serial sectioning [78]. The fact that immunohistochemical
staining increases the identification of metastases has also
been demonstrated in other studies. In their study Lentz et
al., found micrometastases at a rate of 15% in the immu-
nohistochemical examination using antibodies against
cytokeratins AE-1 and CAM 5.2 in early stage cervical can-
cer with negative nodes [79]. Of the patients with
micrometastases, 75% had lymph-vascular space inva-
sion. Therefore, it was argued that immunohistochemical
examination of pelvic nodes could ensure better identifi-
cation of micrometastases in cases with positive lymph-
vascular space invasion [74].
Marchiolè et al. proposed an algorithm based on literature
data and results of their studies. According to this algo-
rithm, adjuvant therapy is not recommended in early
stage cervix tumors which do not have nodal involvement
and lymph-vascular invasion, whereas micrometastasis
should be examined, and if present, adjuvant treatment
should be considered in cases who do not have nodal
involvement, but have lymph-vascular space invasion
[75].
There are also studies reporting that ultrastaging, the most
contemporary and common method recommended for
the identification of micrometastases, and immunohisto-
chemical staining do not increase the identification of
micrometastasis relative to hematoxylin eosin staining
[30]. It is necessary to search new methods that can be
applied to clinical practice due to such results, though
rare, about the clinical value of additional histopatholog-
ical techniques and the inadequate output of available
methods. Of these, the most current ones are flow cytom-
etry and PCR analyses. Reverse-transcriptase PCR appears
to be the most sensitive method to detect metastases. In a
study using reverse-transcriptase PCR, Van Trappen et al.,
found occult micrometastases in 50% of early stage cervi-
cal cancers [80].
Marchiolè et. al. found micrometastases in 5 cases (19%)
with multilevel sectioning followed by cytokeratin immu-
nohistochemistry examinations of the sentinel and non-
sentinel nodes of 26 cases with negative nodes, out of 29
early cervical carcinoma cases in whom laparoscopic lym-
phatic mapping and sentinel lymph node biopsy was per-
formed with patent blue. Of these micrometastases, 2
were identified in the sentinel nodes, and the rest in non-
sentinel nodes. Another highly important finding was that
the cases who had microscopic metastasis in non-sentinel
nodes did not have sentinel node involvement. NPD was
87.5% in this study. Results of the concerned study
require a serious questioning of the sentinel node concept
[53].
Sentinel node biobsy and the future
In consideration of the tendency of study results in the lit-
erature and contemporary medical approach concept
towards non-invasive or at least minimally invasive strat-
egies [81,82], sentinel node procedure, which is mini-
mally invasive, reduces radicalness, and individualizes the
patient and the treatment, appears to be a method that
needs to be concentrated on, and developed as an alterna-
tive to systemic lymphadenectomy, which is considered a
major surgery. Conditions that should be met to ensure
the successful applicability of sentinel node biopsy con-
cept in gynecological cancers and its replacement of con-
ventional methods in the long-term include increasing
experiments related to the method, and presentation of
more results from randomized studies. It is necessary to
establish standards in the field of histopathological exam-
ination, develop frozen examinations, and incorporate
nuclear physics departments into the field in order to
identify micrometastases. In this point, it should be deter-
mined optimal particle size of radioactive tracers and tec-
niqes of preparation in gynecological cancers.
Learning curve is pivotal. This requires including not only
gynecologist oncologists, but also histopathologists and
nuclear physics experts into the subject. All these units in
the centers where lymphatic mapping is performed
should have a sufficient level of knowledge about the con-
cept.
Conclusion
It has been reported extremely interesting results regard-
ing sentinel node cancer and lymphatic mapping proce-
dure in gynecological cancer. We believe that these results
could promise for future gynecological cancer approach.
However, there are further study requirements in patho-
logical, nuclear medicine and gynecological oncology
areas with regarding sentinel node cancer and lymphatic
mapping procedure. This approach has not been in rou-
tine use in clinical medicine. Thus, it is important to sharePage 9 of 12
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vantage obtained from gynecological cancer cases.
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